Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hunting for Cancer's comeback in a drop of blood

NCT ID NCT06605404

Diagnosis Sponsor: Paradigm Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers are collecting blood and tumor tissue samples from people with operable solid tumors, including bladder, esophageal, gastric, melanoma, lung, and pancreatic cancers. Participants receive their usual care while researchers track their health for about five and a half years. The goal is to build a resource that helps develop tests for detecting cancer early and spotting when it might come back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood and tissue sample collection as part of routine cancer care
What this could lead to
If it works, this could lead to blood tests that spot cancer's return earlier, when treatment may work better.
What could go wrong
This is an observational study, so it does not test a treatment. The tests being developed may not prove accurate enough to change how doctors monitor cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Apr 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma esophageal cancer Esophageal Neoplasms exocrine pancreatic carcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma infiltrating bladder urothelial carcinoma melanoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer Gastric and gastroesophageal junction (GEJ) adenocarcinoma Melanoma (skin cancer) Mix of solid tumors (MOST) Muscle invasive bladder urothelial carcinoma NSCLC (non-small cell lung cancer) Pancreatic (exocrine only)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    47 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alabama Oncology

    RECRUITING

    Birmingham, Alabama, 35205, United States

  • Baptist Health Corbin

    RECRUITING

    Corbin, Kentucky, 40701, United States

  • Baptist Health Hardin

    RECRUITING

    Elizabethtown, Kentucky, 42701, United States

  • Baptist Health Lexington

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • Baptist Health Louisville

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • CARTI

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • Cancer & Blood Specialists of Arizona

    RECRUITING

    Casa Grande, Arizona, 85122, United States

  • Cancer Care Associates of York (CCAY)

    RECRUITING

    York, Pennsylvania, 17403, United States

  • Cancer Care Specialists of Illinois (CCSI)

    RECRUITING

    O'Fallon, Illinois, 62269, United States

  • Cancer Center of Kansas

    RECRUITING

    Wichita, Kansas, 67214, United States

  • Cancer Partners of Nebraska

    RECRUITING

    Lincoln, Nebraska, 68516, United States

  • Carle Health

    RECRUITING

    Urbana, Illinois, 61801, United States

  • Carolina Oncology Specialists

    RECRUITING

    Charlotte, North Carolina, 28207, United States

  • Christus Health Highlands

    RECRUITING

    Shreveport, Louisiana, 71105, United States

  • Christus St. Michael's

    RECRUITING

    Texarkana, Texas, 75503, United States

  • Community Clinical Trials

    RECRUITING

    Kingwood, Texas, 77339, United States

  • Comprehensive Hematology Oncology (CHO)

    RECRUITING

    St. Petersburg, Florida, 33709, United States

  • Cotton O'Neil Cancer Center [Stormont Vail]

    RECRUITING

    Topeka, Kansas, 66606, United States

  • Cox Health

    RECRUITING

    Springfield, Missouri, 65807, United States

  • Gabrail Cancer Center

    RECRUITING

    Canton, Ohio, 44718, United States

  • Guthrie Foundation

    RECRUITING

    Sayre, Pennsylvania, 18840, United States

  • Guthrie Lourdes Memorial Hospital (GLMH)

    RECRUITING

    Binghamton, New York, 13905, United States

  • Highlands Oncology Group (HOG)

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Lancaster General Hospital (UPenn)

    RECRUITING

    Lancaster, Pennsylvania, 17601, United States

  • Los Angeles Cancer Network (LACN)

    RECRUITING

    Glendale, California, 91204, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Medical Oncology Associates of San Diego

    RECRUITING

    San Diego, California, 92123, United States

  • Medical Oncology Associates of San Diego (MOASD)

    RECRUITING

    San Diego, California, 92123, United States

  • Mid Florida Cancer Centers

    RECRUITING

    Orange City, Florida, 32763, United States

  • Mohtaseb Cancer Center and Blood Disorders

    RECRUITING

    Bullhead City, Arizona, 86442, United States

  • New York Cancer & Blood Specialists

    RECRUITING

    Shirley, New York, 11967, United States

  • Northwest Medical Specialties (NWMS)

    RECRUITING

    Tacoma, Washington, 98405, United States

  • Oklahoma Cancer Specialists and Research Institute (OCSRI)

    RECRUITING

    Tulsa, Oklahoma, 74129, United States

  • Oncology & Hematology Associates of West Broward

    RECRUITING

    Coral Springs, Florida, 33065, United States

  • Onocology Consultants P.A. (Oncology Consultants [OC Houston])

    RECRUITING

    Houston, Texas, 77030, United States

  • Oregon Health & Science University (OHSU)

    RECRUITING

    Portland, Oregon, 97201, United States

  • Piedmont Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Pontchartrain Cancer Center

    RECRUITING

    Covington, Louisiana, 70433, United States

  • Regional Medical Oncology Center

    RECRUITING

    Wilson, North Carolina, 27893, United States

  • San Juan Oncology Associates

    RECRUITING

    Farmington, New Mexico, 87401, United States

  • Southeastern Medical Oncology Center (SMOC)

    RECRUITING

    Goldsboro, North Carolina, 27534, United States

  • Stockton Hematology Oncology Med Group

    RECRUITING

    Stockton, California, 95204, United States

  • Taylor Cancer Research Center

    RECRUITING

    Maumee, Ohio, 43437, United States

  • The Cancer & Hematology Centers (CHC)

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • The Melanoma and Skin Cancer Institute

    RECRUITING

    Englewood, Colorado, 80113, United States

  • Ventura County Hematology Oncology Specialists

    RECRUITING

    Oxnard, California, 93030, United States

  • Virginia Cancer Institute

    RECRUITING

    Richmond, Virginia, 23229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.